To further validate the therapeutic potential of TPNC, we directly compared their cytotoxic activity against patient-derived ALL cells with that of anti-CD19 CAR-NK cells and primary NK (pNK) cells. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.